AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19128455 — intervention group
Group type: EXPERIMENTAL
Intervention: AS+AQ
Number of subjects: 397
Study 19128455 — intervention group
Group type: EXPERIMENTAL
Intervention: AS+SP
Number of subjects: 397
Study 19128455 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ+SP
Number of subjects: 397
Study 17559990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Number of subjects: 243
Study 17559990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Number of subjects: 243
Study 17559990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IM and IN administration of trivalent inactivated influenza vaccine
Number of subjects: 243
Study 17559990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IN and IM)
Number of subjects: 243
Study 15607399 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chamber detection
Number of subjects: 60
Study 15607399 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber detection
Number of subjects: 60
Study 11792089 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of controlled clinical trials
Number of subjects: 0
Study 11792089 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 9236649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum aspiration
Number of subjects: 140
Study 9236649 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion using mifepristone and gemeprost
Number of subjects: 140
Study 9236649 — intervention group
Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 140
Study 7969677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure oxygen breathing
Number of subjects: 32
Study 7969677 — intervention group
Group type: COMPARATOR
Intervention: Air breathing
Number of subjects: 32
Study 7969677 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-oxygen breathing
Number of subjects: 32
Study 3655856 — intervention group
Group type: COMPARATOR
Intervention: CAF chemotherapy (cyclophosphamide + doxorubicin + 5‐fluorouracil [5‐FU])
Number of subjects: 0
Study 3655856 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF plus tamoxifen (TCAF)
Number of subjects: 0
Study 3655856 — intervention group
Group type: COMPARATOR
Intervention: CAF chemotherapy (for ER+ patients)
Number of subjects: 0
Study 3655856 — intervention group
Group type: COMPARATOR
Intervention: CAF chemotherapy (for ER- patients)
Number of subjects: 0
Study 29023249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Number of subjects: 38
Study 29023249 — intervention group
Group type: COMPARATOR
Intervention: Sham 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Number of subjects: 38
Study 25956688 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 73
Study 25956688 — intervention group
Group type: COMPARATOR
Intervention: Sham kinesiotaping (sham KT)
Number of subjects: 73
Study 24172209 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER (40 to 120 mg/d)
Number of subjects: 434
Study 24172209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 22709688 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count outside of the normal range during follow-up
Number of subjects: 776
Study 22709688 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated WBC count during follow-up
Number of subjects: 776
Study 20155988 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day (monotherapy)
Number of subjects: 46
Study 20155988 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day with pravastatin 10 mg/day
Number of subjects: 46
Study 20155988 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day with rosuvastatin 2.5 mg/day
Number of subjects: 46
Study 20155988 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (both monotherapy and combination therapy)
Number of subjects: 46
Study 18084989 — intervention group
Group type: EXPERIMENTAL
Intervention: Group(VC)
Number of subjects: 88
Study 18084989 — intervention group
Group type: EXPERIMENTAL
Intervention: Group(21cm)
Number of subjects: 88
Study 18084989 — intervention group
Group type: COMPARATOR
Intervention: Group(Cuff)
Number of subjects: 88
Study 16360048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 79
Study 11919665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg on days 1-8, 100 mg on days 9-15)
Number of subjects: 21
Study 11919665 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg on days 1-8, 40 mg on days 9-15)
Number of subjects: 21
Study 11919665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10344359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb concentration of 14 g/dl ([Hb]14)
Number of subjects: 14
Study 10344359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb concentration of 10 g/dl ([Hb]10)
Number of subjects: 14
Study 10344359 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of resting plasma [K+] at [Hb]10 and [Hb]14
Number of subjects: 14
Study 10344359 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta[K+] per unit work performed at different Hb levels
Number of subjects: 14
Study 10344359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate concentration during exercise at both target [Hb] levels
Number of subjects: 14
Study 7628179 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 8
Study 7628179 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study 2035006 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt loading (+6.1 +/- 2.8 g NaCl/d = 105 +/- 48 mmol Na)
Number of subjects: 14
Study 2035006 — intervention group
Group type: COMPARATOR
Intervention: Salt restriction
Number of subjects: 14
Study 2035006 — intervention group
Group type: COMPARATOR
Intervention: Loading with sodium citrate in equimolar concentrations (+140 +/- 40 ml Shohl's solution = 120 +/- 34 mmol Na)
Number of subjects: 14
Study 7237927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cholesterol fat-modified diet (mean 200 mg/day, polyunsaturated/saturated fat ratio of 1.0, 43% of total energy from fat)
Number of subjects: 24
Study 7237927 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched normal subjects)
Number of subjects: 24
Study 31779672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-RDN treatment
Number of subjects: 200
Study 31779672 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (renal angiography alone)
Number of subjects: 200
Study 28425560 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D displays
Number of subjects: 0
Study 25580809 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training followed by clinical training (n = 18)
Number of subjects: 33
Study 25580809 — intervention group
Group type: COMPARATOR
Intervention: Clinical training only (n = 15)
Number of subjects: 33
Study 25064422 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 276
Study 25064422 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 276
Study 22077869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 400 mg
Number of subjects: 13
Study 22077869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19244261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane via vaporizer
Number of subjects: 16
Study 19244261 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane via AnaConDa
Number of subjects: 16
Study 17671114 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aza-2'-deoxycytidine
Number of subjects: 54
Study 17671114 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMP2
Number of subjects: 54
Study 17671114 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of RAMP2 by RNA interference
Number of subjects: 54
Study 17671114 — intervention group
Group type: COMPARATOR
Intervention: Methylation of RAMP2, EFEMP1, and Dutt1
Number of subjects: 54
Study 15310347 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 47
Study 15310347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 47
Study 15310347 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 47
Study 11124777 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 610
Study 11124777 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 610
Study 11124777 — intervention group
Group type: COMPARATOR
Intervention: Control (existing services)
Number of subjects: 610
Study 9594474 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit RCT
Number of subjects: 291
Study 9594474 — intervention group
Group type: COMPARATOR
Intervention: Multiple-visit RCT
Number of subjects: 291
Study 9594474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvital pulp treatment
Number of subjects: 291
Study 7983882 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted terminal cardioplegic solution (n = 10)
Number of subjects: 68
Study 7983882 — intervention group
Group type: COMPARATOR
Intervention: Terminal cardioplegic solution (n = 10)
Number of subjects: 68
Study 7983882 — intervention group
Group type: COMPARATOR
Intervention: Whole blood (n = 10)
Number of subjects: 68
Study 2992785 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine plus cisplatin
Number of subjects: 58
Study 2992785 — intervention group
Group type: COMPARATOR
Intervention: vindesine plus mitomycin
Number of subjects: 58
Study 31602689 — intervention group
Group type: EXPERIMENTAL
Intervention: BaSICS intervention (n = 44)
Number of subjects: 84
Study 31602689 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition (n = 40)
Number of subjects: 84
Study 29806665 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm long × 4 mm wide implants
Number of subjects: 40
Study 29806665 — intervention group
Group type: COMPARATOR
Intervention: Implants of at least 10 mm long
Number of subjects: 40
Study 29806665 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm long implants
Number of subjects: 40
Study 26774401 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement
Number of subjects: 23
Study 26774401 — intervention group
Group type: COMPARATOR
Intervention: No GH replacement (control)
Number of subjects: 23
Study 25370899 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 or XELOX adjuvant chemotherapy
Number of subjects: 517
Study 22486301 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic sympathectomy (VATS)
Number of subjects: 45
Study 22486301 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 45
Study 20452894 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (nucleoside free)
Number of subjects: 168
Study 20452894 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (nucleoside containing)
Number of subjects: 168
Study 20452894 — intervention group
Group type: COMPARATOR
Intervention: No HAART
Number of subjects: 168
Study 20452894 — intervention group
Group type: COMPARATOR
Intervention: No HAART (HIV-negative)
Number of subjects: 168
Study 20452894 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (HIV-positive)
Number of subjects: 168
Study 20452894 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative
Number of subjects: 168
Study 18622282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day
Number of subjects: 89
Study 18622282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 17914655 — intervention group
Group type: EXPERIMENTAL
Intervention: argon plasma coagulation plus imiquimod cream
Number of subjects: 49
Study 17914655 — intervention group
Group type: COMPARATOR
Intervention: argon plasma coagulation alone
Number of subjects: 49
Study 17914655 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients with combination therapy
Number of subjects: 49
Study 17914655 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive patients with monotherapy
Number of subjects: 49
Study 17914655 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative patients
Number of subjects: 49
Study 14681347 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) 300 mg three times a day for 15 days
Number of subjects: 12
Study 14681347 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 400 mg single oral dose
Number of subjects: 12
Study 14681347 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW)
Number of subjects: 12
Study 11010695 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with positive perceived health
Number of subjects: 700
Study 11010695 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility and better physical performance status
Number of subjects: 700
Study 11010695 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of depression
Number of subjects: 700
Study 11010695 — intervention group
Group type: COMPARATOR
Intervention: Gender, limitations in daily living activities, dementia, and utilization of services
Number of subjects: 700
Study 9403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 50 mg
Number of subjects: 4
Study 9403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 100 mg
Number of subjects: 4
Study 9403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 200 mg
Number of subjects: 4
Study 9403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 300 mg
Number of subjects: 4
Study 9403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 500 mg
Number of subjects: 4
Study 9403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 200 mg after a meal
Number of subjects: 4
Study 9403274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 200 mg every 12 h for 7 days
Number of subjects: 4
Study 1488874 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term lowering of glucosylated hemoglobin (HbA1%)
Number of subjects: 45
Study 3548954 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (chronic phase)
Number of subjects: 0
Study 3548954 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline chloride (chronic phase)
Number of subjects: 0
Study 3548954 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus choline chloride (chronic phase)
Number of subjects: 0
Study 3548954 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (chronic phase)
Number of subjects: 0
Study 3548954 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (acute phase)
Number of subjects: 0
Study 3548954 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (acute phase)
Number of subjects: 0
Study 3548954 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (acute phase)
Number of subjects: 0
Study 3548954 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo (acute phase)
Number of subjects: 0
Study 30561029 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium group (Mucilin SF 15.2 g/L added to Blendera)
Number of subjects: 83
Study 30561029 — intervention group
Group type: COMPARATOR
Intervention: Control group (Blendera, fiber-free formula)
Number of subjects: 83
Study 30561029 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium group
Number of subjects: 83
Study 30561029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 27720494 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood harvest (ABH) with simultaneous replacement of blood volume with 1:1 colloid (Tetraspan)
Number of subjects: 50
Study 27720494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ABH)
Number of subjects: 50
Study 27532828 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 300
Study 27532828 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 300
Study 25079708 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline depression symptoms
Number of subjects: 96
Study 25079708 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PTSD symptoms
Number of subjects: 96
Study 25079708 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher traumatic grief symptoms
Number of subjects: 96
Study 25079708 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anxiety symptoms
Number of subjects: 96
Study 25079708 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased depression symptoms
Number of subjects: 96
Study 25079708 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased PTSD symptoms
Number of subjects: 96
Study 22458247 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced total-body CT scan (head to pelvis) during the primary survey
Number of subjects: 0
Study 22458247 — intervention group
Group type: COMPARATOR
Intervention: Conventional trauma imaging protocols supplemented with selective CT scanning
Number of subjects: 0
Study 19735370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (BioSand Filter)
Number of subjects: 59
Study 19735370 — intervention group
Group type: COMPARATOR
Intervention: Control (normal practices)
Number of subjects: 59
Study 19735370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (BioSand Filter) among sub-group using unimproved water sources
Number of subjects: 59
Study 17526594 — intervention group
Group type: EXPERIMENTAL
Intervention: After sales service with supportive supervision
Number of subjects: 713
Study 17526594 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective reimbursement
Number of subjects: 713
Study 17526594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both packages (after sales service with supportive supervision and prospective reimbursement)
Number of subjects: 713
Study 17526594 — intervention group
Group type: COMPARATOR
Intervention: Neither package (control group)
Number of subjects: 713
Study 17526594 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall interventions
Number of subjects: 713
Study 15082421 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil infusion
Number of subjects: 14
Study 15082421 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil infusion
Number of subjects: 14
Study 12790954 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal plug (two sizes tested for 2 weeks each)
Number of subjects: 20
Study 10453752 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 3
Study 10453752 — intervention group
Group type: COMPARATOR
Intervention: No treatment (DSCG non-treated patients)
Number of subjects: 3
Study 10453752 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3
Study 7884019 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg per day
Number of subjects: 32
Study 7884019 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 150 mg per day
Number of subjects: 32
Study 7884019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 150 mg per day
Number of subjects: 32
Study 7884019 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg per day
Number of subjects: 32
Study 3067744 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 2% twice daily
Number of subjects: 0
Study 3067744 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 0
Study 29191844 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low-glucose management (PLGM)
Number of subjects: 154
Study 29191844 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (SAPT)
Number of subjects: 154
Study 27228377 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy (PEG) for 4 weeks or more
Number of subjects: 40
Study 27228377 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric Tube for 4 weeks
Number of subjects: 40
Study 23652840 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian version of Liverpool Care Pathway
Number of subjects: 79
Study 23652840 — intervention group
Group type: COMPARATOR
Intervention: Control (before implementation)
Number of subjects: 79
Study 23516031 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular anesthetic infiltration (PAI)
Number of subjects: 60
Study 23516031 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 60
Study 20543275 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) environment with six video vignettes
Number of subjects: 0
Study 20543275 — intervention group
Group type: COMPARATOR
Intervention: Non-immersive flat screen display
Number of subjects: 0
Study 20543275 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence in VR environment
Number of subjects: 0
Study 18795647 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC/ZG gel (0.10% cetylpyridinium chloride and 0.592% zinc gluconate)
Number of subjects: 0
Study 18795647 — intervention group
Group type: COMPARATOR
Intervention: Control gel (0% CPC and 0.592% ZG)
Number of subjects: 0
Study 16636029 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram hydrochloride 1 mg.kg(‐1) iv
Number of subjects: 60
Study 16636029 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 12100930 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 2% lidocaine gel intrarectally
Number of subjects: 150
Study 12100930 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 1% lidocaine solution periprostatic injection
Number of subjects: 150
Study 12100930 — intervention group
Group type: COMPARATOR
Intervention: No anesthetic (control group)
Number of subjects: 150
Study 10197572 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (4 months duration, 4 days/week attendance, 40-minute sessions, mean heart rate 157 +/- 7 beats/min, mean energy expenditure 946 +/- 201 kJ/session)
Number of subjects: 71